The growing interest in effective weight management has spurred considerable exploration into groundbreaking treatments. Currently, Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist , has exhibited positive results in medical trials, implying potential for substantial weight loss . Therefore,